

Collaborative Working Executive Summary – MFT [Manchester Foundation Trust NHS] and AbbVie

Executive Summary

This is an executive summary outlining collaborative working between AbbVie Ltd and Manchester University NHS Foundation Trust (MFT) focused on developing a high-cost drugs pathway that will improve patient experience, workforce and service capacity to transform care and outcomes for dermatology patients across the Greater Manchester (GM) Healthcare System.

Manchester University NHS Foundation Trust (MFT) is one of the largest acute Trusts in the UK with a core population of approximately 750,000 people from 10 hospitals over 6 sites including Manchester Royal Infirmary, Wythenshawe, Northern General and Trafford General. The catchment area is highly diverse with high deprivation and significant health inequalities.

Project rationale

We are undertaking this collaborative working project as currently patients requiring advanced therapies or biologics for complex dermatology conditions are served by the Northern Care Alliance Trust, specifically at Salford Royal Hospital. Referrals to the Northern Care Alliance from across the Greater Manchester region, which serves a population of 2.8 million, has a significant impact on waiting times, delaying access to treatment and exacerbation of health inequalities.

The purpose of this collaborative working project will be to develop and implement a new advanced therapy/biologics dermatology service at MFT to address challenges and improve the service for both the NHS and the patients.

In undertaking this work, the project team would aim to impact on the following specific outcomes:

- Delivering improved standards of care for patients with psoriasis and atopic dermatitis.
- Develop a patient/high-cost drugs pathway that ensures best value and efficient progression through treatments supporting the transition to advanced therapies, where appropriate.
- Provide patients with pathways to earlier access to advanced therapies, where appropriate.

Project Objectives

Within the project the key objectives are:

- Recruit a dermatology Clinical Nurse and support with training and development in Dermatology and specifically Psoriasis/Atopic Dermatitis.
- Undertake a clinic productivity review of adults treated with advanced therapy/biologics for psoriasis and atopic dermatitis to identify areas of inefficiency such as ‘Did Not Attend’ (DNAs).
- Elevate standards of care by implementing ‘Get it Right First Time’ (GIRFT) recommendations for faster, more equitable care with improvements in the training and function of the MDT.

Collaborative Working Executive Summary – MFT [Manchester Foundation Trust NHS] and AbbVie

- Develop a patient/treatment pathway to include best value use of medicines, reduce variation and improve the uptake of advanced therapy/biologics through early, accurate diagnosis and interventions.

This project will be led by the project NHS Lead, Helen Roberts (Associate Director) & AbbVie Lead, Penny Shaddick (Head of Access). The project effective date will be 1st April 2026 and approximate date for completion would be October 2027.

The Intended Benefits of the Project:

The patient:

- Dermatology patients will receive a more timely, equitable and consistent level of care which adheres to NICE guidelines.
- Patients will have access to clinics that currently do not exist in their geographical area, reducing the need for out-of-area referrals onto lengthy waiting lists.
- Improved patient experience; continuity of care in being seen by same HCP, fewer visits to the hospital and fewer follow-up appointments as outcomes are optimised, and improved availability of healthcare resources to deal with complex cases.

The NHS:

- Implementation of a new model of care with increased capacity to see appropriate dermatology patients.
- Early, accurate diagnosis and interventions aligned to GIRFT recommendations to optimise care and reduce health care resource utilization.
- Optimising the patient journey in dermatology which may reduce the wait time to be prescribed high-cost drugs, removing the need for bridging medication where appropriate which can be ineffective in the long term for patients and have an impact on the capacity and costs associated with healthcare resource utilisation.
- Production of minimum educational operating standards for the whole dermatology multidisciplinary team.
- Improved quality, safety, and effectiveness of a patient pathway with reduced variation and improvement in outcomes.

AbbVie:

- Improved understanding of the treatment/patient pathway for dermatology patients across the Greater Manchester system.
- Opportunity to support the development and delivery of more efficient care pathways for appropriate dermatology patients.
- Enhanced reputation and relationships with NHS partners through successful delivery of scalable, patient-focused solutions.

**Collaborative Working Executive Summary – MFT [Manchester Foundation Trust NHS] and
AbbVie**

Funding

This project will be completed by pooling resources of approximately £150,000 (AbbVie 40%, NHS 60%)

DATE OF PREPARATION March 2026; UK-IMMD-260005

Contact: AbbVie Ltd AbbVie House Vanwall Business Park Vanwall Road Maidenhead Berkshire SL6 4UB

Email: centralisationteam@abbvie.com

This executive summary is published on: www.abbvie.co.uk